MDCX Key Statistics, Chart & Performance
The current stock price of MDCX is 1.57 USD. In the past month the price decreased by -23.41%. In the past year, price decreased by -43.73%.
MDCX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.23 | 404.61B | ||
| AMGN | AMGEN INC | 15.5 | 182.53B | ||
| GILD | GILEAD SCIENCES INC | 15.03 | 152.69B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 27.67 | 121.86B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.88 | 84.60B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 825.51 | 55.62B | ||
| INSM | INSMED INC | N/A | 37.19B | ||
| NTRA | NATERA INC | N/A | 35.03B | ||
| BIIB | BIOGEN INC | 10.95 | 26.90B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.04 | 21.64B | ||
| INCY | INCYTE CORP | 17.23 | 21.72B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.29B |
Related stock screener links
About MDCX
Company Profile
Medicus Pharma Ltd. is a biotech life sciences company, which focuses on accelerating the clinical development programs of novel and disruptive therapeutic assets. The company is headquartered in Conshohocken, Pennsylvania. The company went IPO on 2023-10-11. SkinJect Inc., a wholly owned subsidiary of the Company, is a development stage, life sciences company focused on commercializing novel, non-invasive treatment for basal cell skin cancer using a patented dissolvable microneedle patch to deliver a chemotherapeutic agent to eradicate tumors cells. The company is conducting a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-003) in the United States and Europe. The company has also commenced a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-004) in the UAE. Its subsidiary, Antev Limited, is a late clinical stage biotech company, developing Teverelix, a GnRH antagonist, as a first in market product for cardiovascular high-risk advanced prostate cancer patients and patients with first acute urinary retention relapse episodes due to enlarged prostate.
Company Info
MEDICUS PHARMA LTD
300 Conshohocken State Rd., Suite 200
Conshohocken PENNSYLVANIA US
Employees: 0
Phone: 16105407515
MEDICUS PHARMA LTD / MDCX FAQ
Can you describe the business of MEDICUS PHARMA LTD?
Medicus Pharma Ltd. is a biotech life sciences company, which focuses on accelerating the clinical development programs of novel and disruptive therapeutic assets. The company is headquartered in Conshohocken, Pennsylvania. The company went IPO on 2023-10-11. SkinJect Inc., a wholly owned subsidiary of the Company, is a development stage, life sciences company focused on commercializing novel, non-invasive treatment for basal cell skin cancer using a patented dissolvable microneedle patch to deliver a chemotherapeutic agent to eradicate tumors cells. The company is conducting a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-003) in the United States and Europe. The company has also commenced a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-004) in the UAE. Its subsidiary, Antev Limited, is a late clinical stage biotech company, developing Teverelix, a GnRH antagonist, as a first in market product for cardiovascular high-risk advanced prostate cancer patients and patients with first acute urinary retention relapse episodes due to enlarged prostate.
What is the current price of MDCX stock?
The current stock price of MDCX is 1.57 USD.
Does MDCX stock pay dividends?
MDCX does not pay a dividend.
What is the ChartMill technical and fundamental rating of MDCX stock?
MDCX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Can you provide the market cap for MEDICUS PHARMA LTD?
MEDICUS PHARMA LTD (MDCX) has a market capitalization of 34.59M USD. This makes MDCX a Nano Cap stock.
What is the next earnings date for MDCX stock?
MEDICUS PHARMA LTD (MDCX) will report earnings on 2026-03-23.
MDCX Technical Analysis
MDCX Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to MDCX. MDCX has a bad profitability rating. Also its financial health evaluation is rather negative.
MDCX Financial Highlights
Over the last trailing twelve months MDCX reported a non-GAAP Earnings per Share(EPS) of -1.67. The EPS increased by 27.89% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -195% | ||
| ROE | -319.45% | ||
| Debt/Equity | 0.07 |
MDCX Forecast & Estimates
9 analysts have analysed MDCX and the average price target is 22.78 USD. This implies a price increase of 1350.96% is expected in the next year compared to the current price of 1.57.